Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL S versus TINDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL S versus TINDAL.
MELLARIL-S vs TINDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
TINDAL (trimethoprim) inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate, thereby inhibiting bacterial DNA synthesis.
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
TINDAL (ticarcillin disodium + clavulanate potassium) 3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours. Maximum dose: 18 g ticarcillin/0.6 g clavulanic acid per day.
None Documented
None Documented
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment.
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Primarily renal excretion of unchanged drug (70-80%) and hepatic metabolism (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic